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Studies in various tissues have revealed a central role of metabolic pathways in
regulating adult stem cell function in tissue regeneration and tumor initiation.
The unique metabolic dependences or preferences of adult stem cells, therefore,
are emerging as a new category of therapeutic target. Recently, advanced meth-
ods including high-resolution metabolomics, proteomics, and transcriptomics
have been developed to address the growing interest in stem cell metabolism. A
practical framework integrating the omics analyses is needed to systematically
perform metabolic characterization in a cell-type-specific manner. Here, we
leverage recent advances in transcriptomics and proteomics research to identify
cell-type-specific metabolic features by reconstructing cell identity using genes
and the encoded enzymes involved in major metabolic pathways. We provide
protocols for cell isolation, transcriptome and proteome analyses, and metabo-
lite profiling and measurement. The workflow for mapping cell-type-specific
metabolic signatures presented here, although initially developed for intestinal
crypt cells, can be easily implemented for cell populations in other tissues, and
is highly compatible with most public datasets. © 2021 The Authors. Current
Protocols published by Wiley Periodicals LLC.
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The capacity to adjust metabolic pathways in response to nutrient availability and energy
status is pivotal for cell survival and proliferation. It is generally assumed that unless they
are genetically aberrant, normal cells are equipped with common metabolic machinery
(i.e., transporters and enzymes) to cope with the changing nutritional environment. Cell
metabolism, therefore, is often described as the metabolic reactions in one generic cell,
without a specified cell origin or identity.
Recent studies in stem cell biology suggest a different picture, in which adult stem cells
are metabolically different from their differentiated daughter cells in the same tissue
(Shapira & Christofk, 2020). In the hematopoietic system, metabolic differences between
stem cells and multipotent progenitors can be identified by means of the 160 metabolites
detected in 10,000 flow-sorted cells, using methods involving hydrophilic liquid interac-
tion chromatography and high-sensitivity Orbitrap mass spectrometry (DeVilbiss et al.,
2021). However, it remains difficult to systematically compare metabolite levels between
stem cells and other rare cell populations in solid tissues, such as intestine, mostly due
to the additional dissociation process that is required prior to the flow cytometry−based
cell purification.
In the small intestine, stem cells residing in the crypts of Lieberkühn play a criti-
cal role in epithelial tissue renewal, homeostasis, and cancer development (Calibasi-
Kocal et al., 2021). The balance between self-renewal and differentiation of intesti-
nal stem cells (ISCs) is critically regulated by metabolic pathways. Several metabolic
enzymes and metabolite transporters that mediate ISC glucose metabolism have been
Figure 1 Mapping cell-type-specific metabolic signatures using transcriptome and proteome
analyses. Stem cells and differentiated cell populations purified by flow cytometry are used for
the transcriptome analyses to classify cell-type-specific metabolic gene expression patterns (left)
and/or for proteome analyses to pinpoint stem-cell-specific metabolic enzymes (right). Cross-
referencing the results from two data sets helps identify the stem-cell specific metabolic pathway




identified, including lactate dehydrogenase (LDH), which converts glucose-derived pyru-
vate into lactate in the niche Paneth cells (Rodriguez-Colman et al., 2017), mitochondrial
pyruvate carrier 1 (MPC1), which transports pyruvate into mitochondria in ISCs (Schell
et al., 2017), and pyruvate dehydrogenase (PDH), which converts pyruvate into acetyl-
CoA, thereby increasing the influx of acetyl-CoA from glycolysis into the TCA cycle
(Bensard et al., 2020). These metabolic enzymes act separately in stem cells and niche
cells while coordinately regulating glycolytic and oxidative phosphorylation (OxPhos)
fluxes that critically influence the proliferation and tumorigenic potential of ISCs (Wang,
Odle, & Liu, 2021a), highlighting a significant regulatory role for the metabolic differ-
ences between cell types.
We have recently determined that enzymes mediating lipid metabolism may function as
metabolic cell-fate determinants. Specifically, we found that ISC expressed high levels of
the ketogenic enzyme Hmgcs2 (3-hydroxy-3-methylglutaryl-CoA synthase 2) to produce
the ketone body β-hydroxybutyrate, derived from acetyl CoA produced by fatty acid ox-
idation (FAO). This metabolic feature of ISCs is required for ISC self-renewal, lineage
decision, and adaptation to diet. Here, we will describe the pipeline for experimental
design and analysis that we developed to identify the cell-type-specific metabolic signa-
tures using transcriptome (Cheng et al., 2019; Haber et al., 2017) and proteome analyses
(Gebert et al., 2020; Fig. 1). We will also describe how we use liquid chromatography–




INTESTINAL CRYPT ISOLATION AND CELL POPULATION
PURIFICATION
Cell populations at the bottoms of intestinal crypts serve as an ideal model for studying
the inherent metabolic features of cells. They share the same nutritional environment
while displaying distinct metabolic features (Baulies, Angelis, & Li, 2020; Urbauer,
Rath, & Haller, 2020; Wang, Odle, & Liu, 2021b). Three major cell types enriched in
the intestinal crypts are self-renewing ISCs, transient amplifying (TA) progenitor cells,
and terminally differentiated niche Paneth cells. To enhance the efficiency of purifica-
tion, crypt isolation is a critical step prior to flow-cytometry-based cell sorting. Using a
GFP reporter for Lgr5 (leucine-rich-repeat-containing G-protein-coupled receptor 5, also
known as Gpr49), a marker gene exclusively expressed in cycling columnar ISCs (Barker
et al., 2007), the stem cells and progenitor cells can be distinguished based on GFP in-
tensity. In combination with surface proteins such as c-kit and CD24 that mark secretory
Paneth cells, one can purify the three basic crypt cell populations with one FACS panel:
Lgr5-GFPhigh ISCs, Lgr5-GFPlow progenitors, and c-kit+CD24+ Paneth cells (Cheng,
Yilmaz, & Mihaylova, 2020).
Materials
Mouse (adult, older than 8 weeks)
70% ethanol in spray bottle
500 ml phosphate-buffered saline (PBS; PBS Tablets; Gibco, cat. no. 18912014, to
be dissolved in 500 ml deionized water; keep on ice)
0.5 M disodium EDTA (Promega, cat. no. V4231)
Tweezers
Dissecting scissors
Oral gavage needle on 20-ml syringe
Ice bath
Large petri dish (at least 22 mm)
50-ml conical tubes (e.g., Corning Falcon) Gebert et al.
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Additional reagents and equipment for euthanasia of mice (see Current Protocols
article: Donovan & Brown, 2006)
1. Euthanize mouse by cervical dislocation (see Current Protocols article: Donovan &
Brown, 2006).
2. Place on large lab towel and spray abdomen of mouse with 70% ethanol.
3. Beginning at the base of the abdomen, cut open peritoneal cavity and locate stomach,
usually beneath the liver.
4. Clip beginning of small intestine adjacent to stomach and remove it from the mouse
by pulling until you reach the caecum and colon, readjusting grip every 3-5 cm. Be
sure to remove any fat or blood vessels attached to the intestine.
5. Place small intestine in petri dish containing ice-cold PBS immediately.
6. Keep ice-cold PBS in a separate 50-ml tube to draw from, and use an oral gavage
needle to flush intestine with cold PBS twice into large beaker. First flush from the
proximal end (usually lighter in color), then from the distal end.
7. Open up the intestine (split lengthwise so that it is flat rather than tubular) using the
syringe by inserting the gavage needle into the intestine and gently pulling down the
intestine perpendicular to the tip of the needle, using the needle to cut the intestine.
8. Lay the tissue flat in a petri dish filled with PBS to clean. Gently wipe off excess
mucus and lumen contents.
9. Cut the tissue into 3-5 fragments.
10. Place the tissue into a conical tube with 50 ml cold PBS.
11. Add 1 ml of 0.5 M disodium EDTA to tube with 50 ml PBS and intestine (10 mM
EDTA final).
12. Incubate in cold room on nutating mixer/rocker for ∼45 min.
13. Invert tube 3-5 times and wash by pouring out fluid and refilling the tube with ice-
cold PBS to 30 ml.
14. Shake vigorously in an elliptical motion for 3-5 min until crypts detach from the
intestine.
15. To remove villi from solution, filter the 30 ml of collected crypts through 70-μm
mesh into another clean 50-ml tube.
This is your crypt fraction number 1. See Figure 2A for unfiltered and Figure 2B for
filtered samples.
16. Add another 30 ml PBS to the tube containing the intestine.
17. Repeat steps 13 and 15. Collect up to 6 fractions (∼150 ml).
18. Spin down the collected crypts 5 min at 300 × g, 4°C.





Figure 2 Intestinal crypt isolation for enriching crypt-base cell populations. (A) After EDTA chela-
tion, crypts attached to villi are harvested from mouse small intestine. (B) Crypts are detached by
mechanical disruption and enriched by filtration. Dashed line marks a villus. Arrows indicates to
crypts. Scale bar: 50 μm.
BASIC
PROTOCOL 2
TRANSCRIPTOME ANALYSES FOR CELL-TYPE-SPECIFIC METABOLIC
GENE EXPRESSION
A fundamental question of stem cell biology is what intrinsic features bestow stem cells
with unique properties. Transcriptome analysis, which offers the capability to simultane-
ously discover new transcripts and to quantify gene expression, has been a significant step
toward answering this question. Accompanied by advances in technologies that enable
the quantification of gene expression in rare cell populations, new computational analyses
have been developed to further grant access to the more holistically described cell states
and identities (Morris, 2019). In this protocol, we will explain how we re-define crypt
cell identity with cell-type-specific metabolic gene expression patterns using population
RNA-seq and single-cell RNA-seq data generated from murine intestinal crypt cells.
Materials
Intestinal crypt pellets (see Basic Protocol 1, step 19)
TrypLE (Life Technologies 12604021)
S-MEM (Life Technologies 11380-037)
0.4% BSA: 200 mg of BSA (Sigma-Aldrich A4161) in 50 ml of PBS
15-ml centrifuge tubes (e.g., Corning Falcon)
Low-binding 1.5-ml microcentrifuge tubes
Centrifuge with temperature control (Eppendorf Microcentrifuge 5430 R)
FACSAria3 flow sorter: 4-laser, 11-color sorter running BDFACS Diva software on
XP
Chromium Single Cell Platform (10X Genomics; Cheng et al., 2019)
Qlucore Omics Explorer Version 3.7(21)
R 3.4.0
DESeq2
Seurat v3 (Macosko et al., 2015)
dittoSeq package
Additional reagents and equipment for antibody staining and FACS analysis
(Cheng et al. 2020)
Prepare for fluorescence-activated cell sorting (FACS) for RNA sequencing
1. To prepare samples for cell sorting by flow cytometry, resuspend intestinal crypt
pellets isolated from step 19 of Basic Protocol 1 in 500 μl TrypLE per sample, and
transfer to individual 15-ml Falcon centrifuge tubes. Gebert et al.
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2. Dissociate crypts by incubating with TrypLE for 1 min at 32°C.
3. To stop the dissociation, add 10 ml ice-cold S-MEM and invert the tube twice to
wash the cell pellets.
4. Centrifuge 5 min at 300 × g, 4°C.
5. Remove supernatant and process by antibody staining and FACS analysis as previ-
ously described (Cheng et al., 2020).
6. Sort cells by FACS.
a. Using the FACSAria3 cell sorter for bulk RNA-seq, sort 25,000 live cells
(7AAD−) per population (i.e., Epcam+/CD24-/GFPhigh Lgr5+ ISCs, Epcam+/C
D24-/GFPlow progenitor cells, and Epcam+/GFP-/CD24+/c-Kit+/SSChigh




b. Following the completion of each sort, vortex and place the collected sample on
ice until 200,000 cells have been sorted for each cell population.
c. Perform RNA purification and bulk RNA sequencing as previously described
(Cheng et al., 2020).
d. For single-cell RNA-seq, sort 50,000 live (7AAD-) epithelial cells (Epcam+) into
a 1.5-ml microcentrifuge tube containing 50 μl of 0.4% BSA-PBS and store on
ice.
e. Proceed to the Chromium Single Cell Platform (Cheng et al., 2019).
Briefly, an input of 7,000 cells is added to each channel of a chip with a recovery rate
of 1,500-2,500 cells. The cells are then partitioned into Gel Beads in Emulsion (GEMs)
in the Chromium instrument, where cell lysis and barcoded reverse transcription of RNA
occur, followed by amplification, tagmentation, and 5′ adaptor attachment.
Identify cell-type-specific metabolic gene clusters using bulk RNA-seq data
7. Extract data of 2948 genes encoding mammalian metabolic enzymes using Qlucore
Omics Explorer (Birsoy et al., 2015; Corcoran, Grady, Pisitkun, Parulekar, & Knep-
per, 2017).
8. Filter out lowly expressed genes and genes with small profile variance to reduce
noise. In the current example, we choose to retain genes with the variance (σ/σ max)
greater than 9e-7. In addition, perform multi-group comparison of the cell types by
applying ANOVA using Qlucore Omics Explorer 3.7 or Likelihood Ratio Test (LRT)
using R package DESeq2. Set q-value (i.e., p-value adjusted for multiple testing by
means of false discovery rate, FDR) as selection factor, for example, as q < 0.005.
9. Normalize Z-score (mean = 0, var = 1) and visualize gene-expression levels with
heatmap. To highlight the differences between genes, make Z-score by samples
(force each sample to have zero mean and standard deviation = 1). Center and nor-
malize Z-scores; it also helps to have an intuitive idea of the relative variation.
10. Reorder genes with hierarchical clustering. Depicting the data matrix in this way
puts genes (rows) with similar expression patterns across cell types (columns) close
to each other and helps to find co-varying genes. Three major clusters of genes
are identified based on the cell-type-specific expression patterns (Fig. 3A). Also
see Readme file in the folder containing files generated using Qlucore Omics
Explorer 3.7, available at https://gitlab.leibniz-fli.de/ori-lab/metabolic-signatures-
in-stem-cells/ .
Qlucore Omics Explorer is visualization-based software program for omics data analysis.




Figure 3 Identifying cell-type-specific metabolic gene expression patterns. (A) Results of hier-
archical clustering analysis visualized by a heatmap, showing metabolic gene clusters enriched
for each cell type: (I) Lgr5 high stem cells, (II) Lgr5 low progenitors, and (III) Paneth cells. Blue
to yellow, low to high expression (Z-Score, −2 to 2). (B) Verifying the cell identify-to-metabolism
association using scRNA-seq profiling of 53,193 individual epithelial cells from the mouse small
intestine. Examples of genes identified from the clustering analysis including Hmgcs2 and Cps1




Aligned BAM files (RNA-seq), raw count, and normalized data using the import Wizard
(*.txt, *.tsv, *.csv) and R data frame.
Delineate the cell metabolism−identity patterning using scRNA-seq
11. Cluster the cells using R package Seurat v3 (Macosko et al., 2015).
12. Run non-linear dimensional reduction and visualize cell cluster by t-distributed
stochastic neighborhood embedding Epical cells clustered (t-SNE) or Uniform Man-
ifold Approximation and Projection (UMAP), using RunTSNE() or RunUAMP()
functions, respectively.
13. Annotate cell identity post hocbased on the expression of literature-curated marker
genes. Plot Heatmap shows the relative expression level (row-wise Z scores) of genes
(rows) in cell-type-specific signatures across the individual intestinal epithelial cells
(column) in the full-length scRNA-seq data. This step can be achieved using R,
dittoHeatmap command from dittoSeq package, and the annot.by parameter.
14. Revisit expression of the targeted genes identified in step 10 (e.g., Hmgcs2, Cps1,
Gpx1, ATP2a3, and Apoc2) to examine the cell metabolism−to−cell identity pat-
terning and heterogeneity. Examples shown in Figure 3C are generated using the
single-cell portal (https:// singlecell.broadinstitute.org/single_cell).
This step can also be achieved using R package, Seurat function: FeaturePlot(), and




PROTEOME ANALYSES FOR CELL-TYPE-SPECIFIC METABOLIC
ENZYME LEVELS
The homeostasis of the proteome, also known as proteostasis, is pivotal for the main-
tenance of stem cell function, and its perturbation has been shown to contribute to loss
of regenerative capacity in different stem cell compartments, for example during aging
(Schuler, Gebert, & Ori, 2020). Mass spectrometry−based proteomics enables the quan-
tification of thousands of proteins in cells and tissues. However, the analysis of purified
stem cells has proven challenging due to the limited number of cells that can be ob-
tained from a single animal. Importantly, direct measurement of enzyme levels makes
it possible to take into account both transcriptional and post-transcriptional mechanisms
(e.g., changes in protein synthesis or degradation) that determine the amount of available
proteins in different cell populations (Liu, Beyer, & Aebersold, 2016). The workflow of
sample preparation presented here allows efficient preparation of peptides from a small
number of cells (down to ∼50,000) obtained by FACS. This protocol describes the ap-
propriate collection of ISC populations and preparation as well as analysis of peptides
for the acquisition of the proteomics dataset by LC-MS/MS. The same protocol can be
adapted to any other cell population obtained by FACS, e.g., muscle stem cells (Schuler
et al., 2021).
Materials
Intestinal crypts from step 17 of Basic Protocol 1
Crypt digestion buffer (see recipe; prepare 3 ml/sample)
Phosphate-buffered saline (PBS; PBS Tablets; Gibco, cat. no. 18912014, to be
dissolved in 500 ml deionized water; keep on ice)
Y-27632 dihydrochloride monohydrate (Abcam ab120129)
2× proteomics lysis buffer (see recipe)
1 M dithiothreitol (DTT; Roth 6908.3)
200 mM iodoacetamide (Sigma I1149); prepare fresh directly before use and keep
in the dark (cannot be stored)Gebert et al.
8 of 29
Current Protocols
Acetone (Biosolve 0001037801BS), ice-cold
HPLC water (Sigma 270733)
Protein digestion buffer (see recipe)
LysC stock solution (see recipe)
Trypsin stock solution (see recipe)
10% trifluoroacetic acid (Biosolve 0020234131BS)
Acetonitrile (Biosolve 0001204102BS)
Formic acid (Roth 4724.3)
HRM kit peptides (Biognosys AG 42896)
50-ml conical tubes (e.g., Corning Falcon)
1.5-ml microcentrifuge tubes (Eppendorf 0030120.086)
37°C water bath
Centrifuge with temperature control (Eppendorf 5804R)
70-μm mesh filters
Bioruptor PlusTM (Diagenode)
Thermomixer (Eppendorf 460-0223E and 460-0220)
pH paper (Roth KEE1.1)
Waters Oasis® HLB μElution Plate, 30 μm (Waters 186001828BA)
Extraction Plate Manifold for Oasis 96-Well Plates (Waters 186001831)
Vacuum pump (Gast Manufacturing Inc. DOA P504 PN)
Speed vacuum centrifuge (Eppendorf Concentrator Plus)
PCR tubes (Ratiolab 8610040)
MS vials (VDS Optilab 93909134)
nanoAcquity UPLC system (Waters)
Trapping column (nanoAcquity Symmetry C18, 5 μm, 180 μm × 20 mm; Waters)
Analytical column (nanoAcquity BEH C18, 1.7 μm, 75 μm × 250 mm; Waters)
Orbitrap Fusion Lumos Tribrid Mass Spectrometer (ThermoFisher Scientific)
The outlet of the column needs to be coupled directly to the Orbitrap Fusion Lumos (Ther-
moFisher Scientific) using the Proxeon nanospray source.
SpectronautTM v.14
R v3.6.3
R Studio Server v1.2.5042
Isolating targeted cell populations for proteome analysis
In order to avoid contamination of the sample, nitrile gloves should be used throughout
all the protocol steps. Sample tubes should be resistant to centrifugation at high speed
(20,800 × g) and acetone at indicated steps.
1. Isolate crypts according to Basic Protocol 1, steps 1-17 (collect 3 fractions, combine
fraction 2 and 3, discard fraction 1).
2. For dissociating cells to single-cell suspensions, resuspend crypt pellet (∼400,000
crypts) in 1 ml crypt digestion buffer.
DNase I is added to the crypt digestion buffer to digest DNA released from lysed or apop-
totic cells prior to FACS purification of ISCs.
3. Add an additional 2 ml crypt digestion buffer.
4. Incubate in a water bath at 37°C for 10 min.
5. Vortex 1 min.




7. Fill up to 50 ml with cold PBS containing 80 μM Y-27632 dihydrochloride mono-
hydrate.
Y-27632 dihydrochloride monohydrate is a Rho kinase inhibitor that prevents apoptosis
and thereby increases the number of living cells that can be purified.
8. Centrifuge 5 min at 1000 × g, 4°C.
9. Remove the buffer and resuspend cells in 1 ml PBS containing 80 μM Y-27632
dihydrochloride monohydrate.
10. Filter through a 70-μm mesh directly before sorting.
Dissociated crypts tend to stick back together, so filtration has to be done immediately
before putting the sample in the sorter; otherwise, the sorter might get blocked. In case
sorting takes too long, filter the sample during the process again to dissociate the clotted
cells.
11. Sort two populations of GFP-positive cells (GFPhigh and GFPlow) cells into 1.5-ml
tubes containing 50 μl 2× proteomics lysis buffer:
IMPORTANT NOTE: Make sure that the sample collector of the sorter is not cooling
the samples to temperatures below 20°C. Use tubes for sample collection that are stable
enough for sonication in steps 14 and 16. Clean glassware for preparation of buffers for
proteomics with methanol before use, to remove soap residues.
12. After sorting, spin down samples at room temperature and, if necessary, adjust the
volume of lysis buffer to the volume of sheath fluid collected from the sorter by
adding 2× proteomics lysis buffer.
As an example, if after sorting the sample collection tube contains 150 μl from a starting
volume of 50 μl 2× proteomics lysis buffer, an additional (150 − 50 μl/2 = 50 μl) of
2×proteomics lysis buffer will need to be added to equalize the volumes of concentrated
lysis buffer and collected sheath fluid.
IMPORTANT NOTE: Record the number of sorted cells per sample. This is used to es-
timate the amount of protein to digest for proteomics analysis. An amount of 50-100,000
cells is necessary for continuing with the protocol. Using the described isolation strat-
egy for the cells, 50,000-100,000 ISCs (GFPhigh) or 100,000-200,000 progenitor cells
(GFPlow) can be purified.
13. After sorting, keep the sample on ice until all samples are sorted and frozen, and
store at −80°C until protein digestion and mass spectrometry analysis.
Protein digestion and peptide purification for proteomics
14. Thaw ISC lysates and solubilize by sonication in a Bioruptor PlusTM for 10 cycles
(1 min on and 30 s off), with high intensity, at 20°C.
15. Heat lysates for 10 min at 95°C in a Thermomixer.
16. After heating at 95°C, sonicate lysates again as in step 14.
17. Clarify lysates by centrifugation for 5 min at 20,800 × g, 4°C, in a centrifuge with
temperature control.
18. Transfer the supernatant containing proteins to a new 1.5-ml tube.
Make sure to use tubes that are resistant to acetone!
19. Reduce cysteines by adding 1 M DTT to 10 mM and incubating at 37°C in a Ther-
momixer.
20. Alkylate cysteine by addition of 200 mM iodoacetamide to a final concentration of
15 mM and incubate for 30 min in the dark.Gebert et al.
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Iodoacetamide is not stable and needs to be prepared fresh directly before use and kept
in the dark.
21. Precipitate proteins by adding 8× the sample volume of ice-cold acetone and incu-
bate overnight at -20°C.
22. Pellet the protein by centrifugation for 1 hr at 20,800 × g, 4°C.
23. Remove the supernatant.
24. Wash the pellet twice with ice cold 80% acetone (v/v in HPLC water).
25. Air-dry the pellets in a fume hood.
26. When dried, dissolve the pellet in protein digestion buffer at a concentration of 0.25-
0.5 μg/μl:
27. To facilitate the resuspension of the protein pellet, subject the samples tothree rounds
of sonication (1 min on and 30 s off) with high intensity at 20°C using the Bioruptor
PlusTM.
The amount of protein can be estimated from the number of cells collected by FACS.
For the two populations of ISCs, a protein amount of 5-10 μg per 50,000 cells can be
considered for further calculations.
28. Digest proteins for 4 hr at 37°C using 1:100 (enzyme/protein) LysC.
29. Dilute samples to 1.5 M urea, 50 mM HEPES (see protein digestion buffer recipe)
with HPLC water and digest with 1:100 (enzyme/protein) trypsin for 16 hr at 37°C.
LysC cleaves the proteins at the C-terminus of lysines. The cleavage sites of trypsin are the
C-termini of lysines and arginines. The pre-digestion with LysC allows a more efficient
digestion of the proteins compared to digestion with trypsin only. The dilution before
adding trypsin is necessary because trypsin does not tolerate high levels of urea.
IMPORTANT NOTE: For all the steps where pipetting of peptide solutions is necessary,
use low-binding tips!
30. Acidify digested peptide solutions with 10% trifluoroacetic acid. Check the pH using
0.5 μl sample and pH paper. If the pH is higher than 2, add more trifluoroacetic acid.
31. Desalt the peptides with Waters Oasis® HLB μElution Plate 30 μm:
a. Place a waste collection tray in an Extraction Plate Manifold for Oasis 96-Well
Plates.
b. Condition the columns by applying 3 × 100 μl solvent B (80% acetonitrile/0.05%
formic acid in HPLC water) in presence of a low vacuum of 5 mbar created by a
vacuum pump.
c. Equilibrate the columns by applying 2 × 100 μl solvent A (0.05% formic acid)
in the presence of a low vacuum.
d. Add 100 μl of solvent A without vacuum.
e. Add each sample to one well containing solvent A without vacuum.
f. Load the sample on the column by applying a low vacuum.
g. Wash the samples by adding 3 × 100 μl solvent A in presence of a low vacuum.
h. After the last wash, dry the columns by applying a strong vacuum (up to 10 mbar).
i. Remove the waste collection tray and place PCR tubes for collection of samples.
j. Pipet 50 μl of solvent B and apply low vacuum until all samples are eluted.
k. Dry eluates in a speed vacuum centrifuge.
32. Dissolve the dried peptides in 5% acetonitrile/0.1% formic acid to a peptide concen-





























aNon-linear gradient for the nanoLC during an LC-MS run (step 22). The table shows the runtime (in min) and the
corresponding percentage of mobile phase B (%B) on the column.
33. Transfer 10 μl to an MS vial.
34. Prior to analysis by LC-MS/MS, spike into each sample 0.5 μl of HRM kit peptides
reconstituted according to the manufacturer’s instruction and then diluted 1:4 using
5% acetonitrile/0.1% formic acid.
Label-free LC-MS analysis using Data Independent Acquisition (DIA)
For direct LC-MS analysis using DIA, a volume that contains 1-2 μg of peptides needs
to be injected. The separation gradient is nonlinear, according to Table 1, at a constant
flow of 0.3 μl/min.
Buffers for nanoLC during LC-MS runs: mobile phase A is 0.1% (v/v) formic acid in
water, mobile phase B is 0.1% (v/v) formic acid in acetonitrile.
Degas buffers for nanoLC prior to use by sonication for 15 min in a water bath.
35. DIA data acquisition:
a. Use the nanoAcquity UPLC system fitted with a trapping (nanoAcquity Symme-
try C18, 5 μm, 180 μm × 20 mm) and an analytical column (nanoAcquity BEH
C18, 1.7 μm, 75 μm × 250 mm). The outlet of the column needs to be coupled
directly to an Orbitrap Fusion Lumos using the Proxeon nanospray source.
b. Load 1-2 μg of reconstituted peptides.Gebert et al.
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Table 2 Settings for DIA Mass Spectrometry Data Acquisition on Orbitrap Fusion Lumos Tribrid
Mass Spectrometer (ThermoFisher Scientific)
Entry Parameter Setting
MS OT (scan experiment 1) Detector Type: Orbitrap
0-145 min Resolution 120,000
Mass range Normal
Use quadrupole isolation Yes
Scan Range (m/z) 350-1650
RF lens 30%
AGC target 5.0e5




tMS2 OT HCD (scan
experiment 2)
MSn level 2





HCD collision energy (%) 30
Detector Type Orbitrap
Orbitrap resolution 30,000
Scan range (m/z) 200-2000
AGC target 1.0e6
Maximum Injection Time 70 ms
Microscans 1
Data type Profile





c. Separate peptides using the gradient described in Table 1.
d. Acquire MS data using the parameters described in Table 2.
Proteomics raw data analysis
36. Generate a library by searching DIA raw data using the “directDIA” option in
SpectronautTM v.14 using default settings.
OPTIONAL: Include additional runs based on a Data Dependent Acquisition (DDA)
method (typically a pool of samples for each experimental condition, e.g., 3 pools of
both GFPhigh and GFPlow ISC samples) for spectral library generation using the same
gradient as for DIA (Table 1); the acquisition settings are described in Table 4. In our
experience, inclusion of 4-6 DDA runs generated from the same or comparable samples
as used for DIA analysis increases the number of identifications by 10%-20% at both the
peptide precursor and protein group level.
37. Search DIA raw data against the generated spectral library using default settings. Gebert et al.
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Table 3 The Inclusion List for 34 Variable Window Segments (z = 2 for all) in DIA



































In our experiment, the ISC library contained 59,328 precursors, corresponding to 4814
protein groups, using SpectronautTM protein interference. Typical library recovery was
92.1%.
38. Perform relative quantification in SpectronautTM for each pairwise comparison using
the replicate samples from each condition.
39. Export the data (candidates table) and protein quantity data reports.Gebert et al.
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Table 4 Settings for DDA Mass Spectrometry Data Acquisition on Orbitrap Fusion Lumos Tribrid
Mass Spectrometer (ThermoFisher Scientific)
Entry (node in method editor) Parameter Setting
MS OT Detector Type: Orbitrap
Resolution 60,000
Mass range Normal
Use quadrupole isolation Yes
Scan Range (m/z) 350-1650
RF lens 40%
AGC target 2.0e5




MIPS Monoisotopic peak determination Peptide
Intensity Filter type, Intensity threshold 5.0e4
Charge state Include charge state(s) 2-7
Dynamic exclusion Exclude after n times 1
Exclusion duration (s) Depends on LC runtime:






ddMS2 IT HCD Isolation mode Quadrupole
Isolation Window (m/z) 1.4
Activation type HCD
HCD collision energy (%) 30
Detector type Orbitrap
Resolution 15,000
First mass (m/z) 120
AGC target 2.0e5
Maximum Injection Time 22 ms
Microscans 1
Data type Profile
Data Dependent Properties Select: “Cycle time” 3 s
SpectronautTM is a commercial software that is routinely used in our laboratory (Bruderer
et al., 2019). Alternative software for analysis of DIA data are DIA-NN, OpenSWATH,
Skyline, PeaksDIA, and DIA-Umpire (Demichev, Messner, Vernardis, Lilley, & Ralser,
2020; Pino et al., 2020; Rost, Aebersold, & Schubert, 2017; Tran et al., 2019). We re-





Proteomics data analysis using R
Downstream data analyses and visualization can be performed using R v3.6.3 in R Studio
Server v1.2.5042 using a similar strategy to the one for population RNA-seq (Fig. 4A).
40. Perform principal component analysis (PCA) using all the quantified proteins to
compare samples.
a. Extract protein intensities (“PG.quantity” from Spectronaut report table), log2
transform, perform PCA using the function prcomp, and visualize results using
the function fviz_pca_ind, which is part of the package factoextra (https://cran.
r-project.org/package=factoextra).
b. Samples from different cell populations should form clearly distinguishable clus-
ters on the PCA space (Fig. 1, proteome analyses). Possible outlier samples can
also be identified with this procedure and removed for downstream analysis.
41. Analyze the abundance of metabolic enzymes quantified.
a. Extract protein intensities from the Spectronaut report table for the 2948 genes
encoding mammalian metabolic enzymes (Birsoy et al., 2015).
b. Filter for proteins showing differential abundance between cell types according to
the Spectronaut candidates table. Here, proteins are retained if q value is smaller
than 0.05 and the absolute log2 fold change (“Absolute.AVG.Log2.Ratio”) is
greater than 0.3.
In our dataset, we quantified 393 metabolic enzymes with q < 0.05 and absolute log2
fold change >0.3.
c. Normalize data via Z-score (mean = 0, var = 1) and visualize protein levels with
heatmap. To highlight the differences between proteins, make Z-score by sample
(force each sample to have zero mean and standard deviation = 1).
In general, centering and normalizing Z-scores also help in getting an intuitive idea of
the relative variation.
d. Reorder genes with hierarchical clustering. Depicting the data matrix in this way
puts genes (rows) with similar expression patterns across cell types (columns)
close to each other and helps to find co-varying proteins. In Figure 4B, two
major clusters of proteins are identified based on the cell-type-specific expres-
sion patterns.
Z-score-based analysis is powerful for identifying robust differences between cell types;
however, in order to estimate the effect size of protein abundance differences between
samples, complementary approaches should be used. In particular, proteomics data al-
low one to estimate absolute amounts of proteins and, thereby, to compare directly the
abundance of metabolic enzymes in different sample types.
e. Protein abundance estimates can be derived from the intensities of the peptides
identified for each protein. Default settings in Spectronaut utilize a Top3 strategy
for peptide summarization, whereby the mean value of the three most confidently
identified peptides for each protein is used to derive the protein abundance value.
Since this strategy considers the same number of peptides for each protein, it does
not require further normalization to take into account differences in protein sizes.
Other summarization strategies, i.e., based on summed peptide intensities, require
additional normalization steps to derive comparable estimates of protein absolute
abundances (see for example iBAQ values; Schwanhausser et al., 2011).
In order to correctly estimate abundances of related (homologous) proteins, only proteo-
typic peptides (peptides unique to a given gene product) should be used. In addition, it is
recommended to consider only proteins for which at least two proteotypic peptides were
identified, as abundance estimates based on single peptides can be less accurate due to


























































































































































































































f. In Figure 4C, absolute levels of key rate-limiting metabolic enzymes are com-
pared between GFPhigh and GFPlow ISC samples. Illustrative R code and input




METABOLITE PROFILING AND MEASUREMENT
In contrast to RNA and proteins, metabolites do not follow a fixed structural template and
accordingly have diverse physical properties. As a result, no single analytical tool can
measure all metabolites. One advantage of the current framework is that once the cell-
type-specific metabolic genes or enzymes are identified, the targeted metabolic pathways
can be further investigated in combination with metabolic gene ablation. Here, we use
Hmgcs2 and ketogenesis (i.e., ketone body metabolite production), which we identified
as ISC-specific metabolic signature, as an example to describe the validation process us-
ing HRAM (high-resolution accurate-mass) liquid chromatography–mass spectrometry
(LC–MS) (”a” steps below) and NAD+/NADH assay (”b” steps below) for measuring ke-
tone body β-hydroxybutyrate (β-OHB). The former provides overall changes of relative
metabolite levels in response to the target gene deletion. The latter is designed specifi-
cally for determining levels of the targeted metabolite β-OHB, which is based upon the
oxidation of D-3-hydroxybutyrate to acetoacetate by the enzyme 3-hydroxybutyrate de-
hydrogenase (McMurray, Blanchflower, & Rice, 1984).
Materials
LC/MS OPTIMA−grade methanol (Fisher Scientific A4564)
Metabolomics Amino Acid Mix Standard (Cambridge Isotope Laboratories, Inc.
MSK-A2-1.2)
CIL has since brought out a new Canonical Amino Acid Standard Mix (MSK-CAA-1)
which contains all 20 proteogenic amino acids labeled with 13C and 15N; we recommend
using this as an internal standard option instead.
Blood bank saline, 0.85% NaCl (Azer Scientific 16005-092)
LC/MS OPTIMA−grade water (Fisher Scientific W64)
LC/MS grade chloroform with ethanol as a stabilizer (Fisher Scientific C606SK1)
LC/MS OPTIMA grade acetonitrile (Fisher Scientific A9554)
Ammonium carbonate (Sigma 379999)
Ammonium hydroxide (Sigma 338818)
100 mM Tris·HCl, pH 8.5
β-Hydoxybutyrate Standard (Sigma H0265)
β-Hydoxybutyrate Enzyme Solution (Caymen 700193)
β-Hydroxybutyrate Colorimetric Detector (Caymen 700194)
Glycine (Sigma G7126)
Aspartate (Sigma A7219)
1.5-ml microcentrifuge tubes (Axygen MCT-150-C)
Centrifuge with temperature control (Eppendorf 5804R)
Nitrogen evaporator (MultiVap, Organomation)
Polypropylene autosampler vials with fused insert (ThermoFisher 03340620)
Autosampler caps with PTFE/silicone septa (ThermoFisher 03376481)
Dionex Ultimate 3000 UHPLC (ThermoFisher Scientific)
QExactive hybrid mass spectrometer equipped with a HESI II probe
(ThermoFisher Scientific)
SeQuant® ZIC-pHILIC analytical column (5 μm, 150 × 2.1 mm) fitted with a





TraceFinder 4.1 (ThermoFisher Scientific)
96-well plates for colorimetric assays
NOTE: If absolute quantification of metabolites is required, we recommend including the
labeled metabolite of interest as an internal standard if possible, and running a standard
curve alongside the experimental samples. Determining cell number and volume/ tissue
weight is also required to calculate absolute concentration.
Polar metabolite extraction and detection using HRAM LC/MS
Chloroform-methanol extraction
Before you begin, prepare methanol containing 500 nM Metabolomics Amino Acid Mix
Standard (methanol with internal standards) and chill to −20°C (this can be stored long-
term at −20°C). Chill appropriate amount of chloroform to −20°C and LC/MS grade
water to 4°C. The following protocol should be performed on ice and as quickly as pos-
sible to quench metabolism in the intestinal crypts.
1a. Harvest intestinal crypts from WT and Hmgcs2-intestinal KO mice as previously
described (Cheng et al., 2020; also see Basic Protocol 1).
2a. Wash crypt pellets once with cold 0.85% NaCl.
3a. Add 600 μl LC/MS-grade methanol with internal standards.
4a. Add 300 μl LC/MS-grade water.
5a. Pipette up and down to mix.
6a. Add 400 μl chloroform to each sample.
7a. Vortex for 10 min at 4°C
8a. Spin 10 min at 21,100 × g, 4°C, to initiate phase separation.
9a. Carefully collect the two layers separately, avoiding the precipitate at the interface
of the two layers (top layer is polar; bottom layer is organic/lipids). Evaporate to
dryness under a stream of nitrogen.
10a. Store dried polar and organic extracts at −80°C until analysis.
Organic extracts can be used for lipidomics analysis, the method for which is beyond
the scope of this protocol.
Preparation of samples for LC-MS analysis of polar metabolites
11a. Resuspend dried polar extracts in 100 μl LC/MS-grade water (on ice)
12a. Vortex for 10 min at 4°C to ensure complete resuspension and even mixing
13a. Spin for 10 min at 21,100 × g, 4°C, to remove any remaining debris/precipitate
14a. Transfer 90 μl to a new 1.5-ml microcentrifuge tube (on ice)
15a. Combine equal volumes of each sample to create a 1× pooled sample (this will be
used for QC).
The volume you will need from each sample will depend on the number of samples in
the overall experiment.
16a. Take 3 μl of your pooled sample and add 7 μl LC/MS-grade water. This will be
your 0.3× dilution. Transfer to an LC/MS autosampler vial.
17a. Take 1 μl of your pooled sample and add 9 μl LC/MS-grade water. This will be
your 0.1× dilution. Transfer to an LC/MS autosampler vial. Gebert et al.
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aLinear gradient for the UHPLC during an LC-MS run (step 21a). The table shows the runtime (in min) and the corre-
sponding percentage of mobile phase B (%B) on the column.
18a. Transfer at least 40 μl of your 1× pooled sample to an LC/MS autosampler vial.
19a. Transfer 20 μl of sample to an LC/MS autosampler vial. Store any remaining sam-
ple (from the original 90 μl resuspension) at −80°C as a backup in case the initial
run fails.
20a. Transfer LC/MS vials to the autosampler of the LC system
LC-MS analysis of polar metabolites
For LC-MS analysis of polar metabolites inject 2 μl of each sample. Metabolites are
separated on a Dionex Ultimate 3000 UHPLC using a linear gradient according to
Table 5 with a constant flow rate of 0.15 ml/min.
Other LC systems may be used. However, the technology transfer may need to be deter-
mined empirically.
Mobile Phase A: 20 mM ammonium carbonate with 0.1% ammonium hydroxide
Mobile Phase B: acetonitrile
The following MS parameters are specific to the QExactive quadrupole-orbitrap hybrid
mass spectrometer (ThermoFisher Scientific). While alternative mass spectrometers may
be used, their parameters will need to be adjusted according to the specific instrument
being utilized.
21a. Data acquisition:
i. Use the Dionex UltiMate 3000 UHPLC system coupled to a QExactive hybrid
mass spectrometer equipped with a HESI II probe.
ii. Prior to analysis, calibrate the mass spectrometer using the standard calibra-
tion mix if calibration has not been performed within the last 7 days, or a
mass check fails. Perform a custom calibration of the lower end masses by
spiking the standard calibration mix with glycine (positive ionization mode)
and aspartate (negative ionization mode).
iii. Inject 2 μl sample onto a SeQuant® ZIC-pHILIC analytical column (5 μm,
150 × 2.1 mm) fitted with a SeQuant® ZIC-pHILIC guard column (5 μm, 20
× 2.1 mm).
Note that injection volume may need to be determined empirically depending on the
cell/tissue type. Choose an injection volume that detects metabolites in the linear range
(use the linear dilution series to determine the linear range of each metabolite).
iv. Set the column oven to 25°C and the autosampler tray to 4°C.
v. Use Excel to randomize the order in which your samples will be injected and
inject the pooled QC sample every 8-10 samples, including the 0.3× and 0.1×
dilution series at the end of your sequence. As part of this linear dilution series,
include a larger 2× QC pool injection. In addition, acquire MS/MS data from




Table 6 Settings for Full-Scan Polarity Switch with tSIM for β-OHB Mass Spectrometry Data Ac-
quisition on QExactive Hybrid Mass Spectrometer (ThermoFisher Scientific)
Entry Parameter Setting
Full MS Polarity Positive
0-16.5 min Resolution 70,000
AGC Target 1e6
Max IT 20 ms
Microscans 1
Data Type Profile
Scan Range 70-1000 m/z
Full MS Polarity Negative
0-16.5 min Resolution 70,000
AGC Target 1e6
Max IT 20 ms
Microscans 1
Data Type Profile
Scan Range 70-1000 m/z
tSIM Polarity Negative
3-7 min Inclusion list On: 120.03230 m/z
Resolution 70,000
AGC Target 1e5
Max IT 250 ms
Isolation Window 1.2 m/z
Microscans 1
Data Type Profile
vi. Separate metabolites using the gradient described in Table 5.
vii. Acquire MS data using the parameters described in Tables 6-8.
Processing and analysis of LC-MS data to determine relative quantification of polar
metabolites
22a. Use TraceFinder 4.1 to integrate raw peak areas for metabolites of interest and
internal standards by extracting ion chromatograms from the full scan data (or tSIM
data in the example of β-OHB)
i. For metabolite identification, match retention time and MS/MS spectra against
in-house retention time and MS/MS spectral libraries previously established us-
ing identical LC-MS conditions and authentic chemical standards.
The in-house retention time library is especially important for the integra-
tion of β-hydroxybutyrate due to close-eluting isomers of α-hydroxybutyrate, β-
isohydroxybutyrate, and γ -hydroxybutyrate.
23a. Normalize raw peak areas by dividing the raw peak area for each metabolite by the
raw peak area of the corresponding internal standard (selected based on similarity
of retention time and/or chemical similarity). If performing metabolite profiling
to measure a particular metabolite, consider purchasing a stable isotope−labeled
version of that metabolite if available.
24a. Further normalize these values to tissue weight (mg) or cell number, if the extrac-
tion volume was not adjusted for biological input prior to analysis by LC-MS. Gebert et al.
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Table 7 Settings for ddMS2 Positive Mode Mass Spectrometry Data Acquisition on QExactive
Hybrid Mass Spectrometer (ThermoFisher Scientific)
Entry Parameter Setting
Full MS Polarity Positive





Max IT 50 ms
Microscans 1
Data Type Profile
Scan Range 70-1000 m/z
ddMS2 Resolution 17,500
AGC Target 2e5
Maximum IT 100 ms
Loop Count 10
TopN 10
Isolation Window 1.0 m/z
dd properties (N)CE/Stepped (N)CE 15, 30, 45
Exclude Isotopes On
Dynamic Exclusion 5.0 s
aExclusion list for positive mode should be generated prior to experiment using a mock extraction run on identical Full
Scan settings. Include the top 100 most abundant ions.
25a. Generate QC metrics by calculating the coefficient of variation (CV) for the multi-
ple pooled QC injections. Reject metabolites with a CV >0.25, as these metabolites
are not being detected in a reliable fashion.
26a. Use the pooled dilution series (average of pooled 1× QC injections, 0.3× QC pool
injection, and 0.1× QC pool injection) to calculate the linear correlation coefficient
for each metabolite. Reject metabolites that have an R value of <0.975, as these
metabolites are not being detected in a linear fashion.
27a. Use the normalized values to calculate relative log2 fold change across different
conditions and to perform statistical analysis. Many open-source platforms ex-
ist that can be used for this purpose, including Metaboanalyst (Xia, Psychogios,
Young, & Wishart, 2009).
Because the levels of metabolites being detected here are relative, comparisons can only
be made by comparing relative levels of the same metabolite across different conditions
in the same base sample type (i.e., by comparing relative levels of β-hydroxybutyrate
across intestinal crypts isolated from wt and KO mice). It is not possible to compare
levels of different metabolites within the same sample due to ionization suppression and
enhancement, and other matrix effects that can occur during ESI. To compare levels of
different metabolites within the same sample, absolute molar quantification is required.
Similarly, it would be inappropriate to compare relative levels of the same metabolite
across samples of different types (i.e., comparing levels of β-hydroxybutyrate between




Table 8 Settings for ddMS2 Negative Mode Mass Spectrometry Data Acquisition on QExactive
Hybrid Mass Spectrometer (ThermoFisher Scientific)
Entry Parameter Setting
Full MS Polarity Negative





Max IT 50 ms
Microscans 1
Data Type Profile
Scan Range 70-1000 m/z
ddMS2 Resolution 17,500
AGC Target 2e5
Maximum IT 100 ms
Loop Count 10
TopN 10
Isolation Window 1.0 m/z
(N)CE/Stepped (N)CE 15, 30, 45
dd properties Exclude Isotopes On
Dynamic Exclusion 5.0 s
aExclusion list for negative mode should be generated prior to experiment using a mock extraction run on identical Full
Scan settings. Include the top 100 most abundant ions.
NAD+/NADH assay for β-OHB determination
1b. Resuspend the crypt cells from Basic Protocol 1 (step 19) or directly sort cell pop-
ulations from Basic Protocol 2 (step 6) in 50 μl 100 mM Tris·HCl, pH 8.5.
2b. Homogenize the cell suspension on ice.
3b. Centrifuge cell suspension 10 min at 10,000 × g, 4°C.
4b. Transfer the supernatant to another tube on ice
5b. Prepare standards by serially diluting β-hydroxybutyrate solution (50 μl each, from
100 to 1 μM) using 100 mM Tris·HCl.
6b. Load standard duplicates and samples into 96-well microplate for colorimetric as-
say. Use 100 mM Tris·HCl as the blank for calibration.
7b. Prepare developer solution by mixing 100 μl of the β-HB Colorimetric Detector to
the vial of reconstituted β-HB Enzyme Solution. Store the developer solution on
ice.
8b. Add 50 μl developer solution to each well and mix the reagents by pipetting to
initiate the enzymatic reaction
9b. Incubate the plate in dark, at 25°C, up to 2 hr for lysates from crypts or up to 6 hr
for lysates from sorted cells.
10b. Read the absorbance at 445-455 nm.
11b. Calculate the average absorbance of each standard and sample. Gebert et al.
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12b. Subtract the absorbance value of standard A (0 mM) from itself and all other values
(both standards and samples).
This is the corrected absorbance.
13b. Calculate the values of the β-HB samples using the equation obtained from the
linear regression of the standard curve by substituting the corrected absorbance
values for each sample into the equation.




0.4 U/μl DNase I (Sigma 4716728001)
5 mM MgCl2 (Roth KK36.2)
80 μM Y-27632 dihydrochloride monohydrate (Abcam ab120129)
Prepare fresh before use
LysC stock solution
Prepare a stock solution of LysC (Wako Chemicals GmbH 125-05061) at a concen-
tration of 0.5 μg/μl by reconstituting lyophilized enzyme (20 μg vial) in 40 μl. LysC
stock solution can be stored at −20°C for up to 1 year. Avoid multiple cycles of
freeze-thawing.
Protein digestion buffer
Prepare in HPLC water (Sigma 270733):
3 M urea (Sigma, U6504)
100 mM HEPES (Sigma, H3375), pH 8
Prepare fresh before use
Proteomics lysis buffer, 2×
Prepare in MilliQ water:
4% sodium dodecyl sulfate (SDS; Sigma 75746)
200 mM HEPES (Sigma H3375), pH 8 (adjust with NaOH)
20 mM dithiothreitol (DTT; Roth 6908.3)
Store up to 1 week at −20°C
Since SDS might precipitate at low temperature, do not keep the proteomics lysis
buffer on ice!
Trypsin stock solution
Prepare a trypsin stock solution at a concentration of 0.5 μg/μl by reconstituting
lyophilized enzyme (Promega, V5111; 20 μg vial) in 40 μl of provided trypsin buffer
(supplied with the enzyme). Trypsin stock solution can be stored at −80°C for up to
1 year. Avoid multiple cycles of freeze-thawing.
COMMENTARY
Background Information
The concept of cell identity has evolved
with methods that allow detecting cell fea-
tures for classification. Although transcrip-
tome and proteome analyses are primary ap-
proaches for studying cell identity, they have
not been utilized for discovering cell-type-
specific metabolic features until very recently
(Cheng et al., 2019; Gebert et al., 2020). In this
protocol, we use intestinal crypts as an exam-
ple to describe the essential steps involved in
tissue dissociation and cell population purifi-
cation (Basic Protocol 1). We explain how to
cross-reference transcriptome (Basic ProtocolGebert et al.
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2) and proteome (Basic Protocol 3) data and
use these data as an exploratory tool to identify
inherent metabolic features in different cell
types. We use ketogenic HMGCS2 and ketone
body metabolites as examples to describe how
to further investigate the metabolic activities
by metabolite profiling (Basic Protocol 4).
The integrative framework offers sev-
eral advantages in identifying the cell-
type-specific metabolic features. First, the
transcriptome and proteome-based analy-
ses allow immediate discovery of the cell
marker−to−metabolism association and the
more advanced pathway analyses linking the
differentially expressed metabolic enzymes
to the cell-fate determination signaling. Also,
genetic or enzymatic perturbations can be
directly applied to the screening pipeline for
downstream functional validation. Signifi-
cantly, this approach narrows down the pool
of metabolite candidates, which eases the
technical hurdles of measuring a wide breadth
of small molecules in rare cell populations
or transient cell states. Finally, compared to
the metabolome datasets, many more tran-
scriptome and proteome datasets containing
cell-type-specific information are publicly
available. Therefore, biologists are much
more encouraged to explore the cell-type-
specific metabolic signatures in the tissues or
diseases of interest using transcriptomics and
proteomics approaches.
Data Interpretation
The differential expression of metabolic
genes/proteins identified in Basic Protocols 2
and 3 (Fig. 3A and 4A) reveals the inherent
metabolic differences interlinked with the de-
fined cell types. When mapping the expression
pattern of the identified genes/proteins onto
tSNE plots (Fig. 3B), one can further visualize
heterogeneity of metabolic features within the
stem cell cluster and more holistically explore
the relationship between the metabolic fea-
tures and cell states and identities at single-cell
resolution. For example, Hmgcs2 enriching
for Lgr5high stem cells (Fig. 3A, cluster I) is
expressed moderately in transient amplifying
progenitor cells at G2/M phase (TA-G2) but
sparsely in TAs at G1/S phase (TA-G1) (Fig.
3B). Cps1 expression is fairly high in stem and
progenitor clusters, but very low in the differ-
entiated cells (i.e., enterocytes, goblet, Paneth,
tuft, and enteroendocrine cells). Expression
of Gpx1 enriching for the Lgr5low TAs (Fig.
3A, cluster II) is particularly up-regulated in
TAs and early progenitors, but significantly
down-regulated in the terminally differenti-
ated cells. Similarly, Itpka (Fig. 3A, cluster
II) expression is almost exclusive to TAs and
progenitors. Finally, the result of scRNA-seq
indicates that Atp2a3 and Apoc2 identified
through the enrichment in CD24+ Paneth
cells (Fig. 3A, cluster III) are not specific to
the Paneth cell cluster. In fact, the data shows
that genes highlighted in cluster III (Fig. 3A)
mostly are markers for the terminally differ-
entiated cells. Atp2a3, for example, marks the
goblet and Tuft cells, and Apoc2 is almost
exclusively expressed in the enterocytes.
Overall, these data indicate a great diversity
of metabolic gene and protein expression pat-
terns across cell types. They also highlight the
utility of transcriptome and proteome analyses
for systematically exploring the relationship
between cell metabolism and identity.
It is worth mentioning that differential
metabolic gene expression is not always
consistent with protein levels. In Figure 4C,
we examine the gene expression and protein
levels of the rate-limiting enzymes of twelve
major metabolic pathways in Lgr5high stem
cells and Lgr5low progenitors. The differential
expressions of Cps1 for urea cycle, Hmgcs1
for cholesterol synthesis, Hmgcs2 for ketoge-
nesis, and Idh1 for TCA cycles are consistent
at both RNA and protein levels. Cpt1a for
fatty acid oxidation is higher in the progenitor
at RNA levels but not at protein levels, which
is the opposite of Fasn and Fbp1 expression.
Cpt1b and Cpt1c (isoforms of Cpt1a), Gys1
for glycogen synthesis, Pfkm for glycolysis,
and Ppat for purine synthesis are not de-
tectable at protein levels. The consistency be-
tween RNA and protein profiles of the targeted
genes can also serve as the selection criterion
for robust inherent metabolic features. Given
that rate-limiting enzymes catalyze specific
reactions at a relatively lower velocity and
in a relatively substrate-independent manner,
one can further investigate the metabolic
activity based on the levels of corresponding
metabolites (Fig. 5). As described in Basic
Protocol 4, to investigate the metabolic activ-
ity of HMGCS2, one can measure the levels
of acetoacetate (AcAc) β-hydroxybutyrate
(β-OHB; Fig. 5, ketogenesis) using HRAM
LC/MS (Basic Protocol 4, ‘a’ steps) and β-
OHB specifically NAD+/NADH assay (Basic
Protocol 4, ‘b’ steps).
Alternative Methods
Although we are able to distinguish 153
polar metabolites, with 108 metabolites de-
tected in intestinal crypts, using the HRAM




Figure 5 Substrates and metabolic products of rate-limiting enzymes. HMG-CoA synthase 1
(HMGCS1) catalyze the condensation of acetyl-CoA with acetoacetyl-CoA to HMG-CoA for meval-
onate production, the first rate-limiting step of cholesterol synthesis. Carnitine palmitoyltransferase
(CPT) catalyzes the transport of long-chain fatty acids into mitochondria, the rate-limiting step
of fatty acid oxidation, by converting fatty acyl-CoAs into acyl-carnitines. In de novo fatty acid
synthesis, fatty acid synthase (FASN) catalyzes malonyl-coenzyme A (CoA) to provide the pri-
mary carbon source for the formation of long-chain fatty acids such as palmitate. Fructose 1,6-
bisphosphotase (FBP) catalyzes the dephosphorylation of fructose-1,6 bisphosphate (fructose-
1,6BP) to fructose-6 phosphate, the rate-limiting step of gluconeogenesis. Glycogen synthase
(GYS) catalyzes the conversion of UDP-glucose to glycogen by the addition of a α-1,4-glycosidic
bond between an existing glycogen chain and glucose, the rate-limiting step of glycogenesis. Phos-
phofructokinase (PFKM) catalyzes the phosphorylation of fructose-6 phosphate to fructose-1,6
bisphosphate (fructose-1,6BP), the rate-limiting step of glycolysis. Glucose 6-phosphate dehydro-
genase (G6PDH) converts glucose 6-phosphate into 6-phosphogluconate, the rate-limiting step
of HMP shunt. 3-Hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) condenses acetoacetyl-
CoA (AcAc-CoA) to form HMG-CoA, the rate-limiting step of ketogenesis, by the addition of
acetyl-CoA. Phosphoribosyl pyrophosphate amidotransferase (PPAT) catalyzes the conversion of
5-phosphoribosyl-1-pyrophosphate into 5-phosphoribosyl-1-amine using the amine group from a
glutamine side chain, the committing step of de novo purine synthesis. Carbamoyl-phosphate
synthetase-2-aspartate transcarbamylase-dihydroorotase enzyme (CAD) utilizes glutamine and
aspartate to synthesize dihydroorotate, the rate-limiting step of de novo pyrimidine biosynthesis.
Isocitrate dehydrogenase (IDH) catalyzes the conversion of isocitrate to α-ketoglutarate through ox-
idative decarboxylation, the rate-limiting step of the TCA cycle. Carbamoyl phosphate synthetase
(CPS) catalyzes the conversion of ammonia or glutamine to carbamoyl phosphate in the rate-




Basic Protocol 4, we encourage readers to
modify the extraction protocol or to consider
alternative methods optimized for the metabo-
lites of interest. Gas chromatography−mass
spectrometry (GC-MS)−based metabolite
profiling, for instance, is ideal for identifying
and quantitating small molecular metabolites
(<650 Da), such as small acids, alcohols,
sugars, and sterols (see Current Protocols
article: Fiehn, 2016). In addition to MS-
based methods, nuclear magnetic resonance
(NMR) technologies have also been used
for metabolite profiling (Perez-Ramirez &
Christofk, 2021). The NMR-based techniques
offer a better resolution for the difficult-to-
distinguish metabolites. However, they have
lower sensitivity compared to MS, and are
therefore more suitable for abundant metabo-
lites or large cell populations in the tissue
(Perez-Ramirez & Christofk, 2021). Because
we incorporate the metabolite profiling and
measurement here for target validation instead
of data exploration, readers can also take ad-
vantage of the target-driven approach using
assays developed for specific metabolites. For
example, the NAD+/NADH assay described
in the ‘b’ steps of Basic Protocol 4 is special-
ized for measuring levels of β-OHB. There
are also commercially available biolumines-
cent assays to detect the levels of glucose,
glutamine, glutamate, and lactate at nanomo-
lar (nM) concentrations from cell lysates.
Also, for rate-limiting enzymes that catalyze
specific metabolites (Fig. 5), metabolic flux
analysis using stable isotope-labeled tracers
will allow a dynamic profile of the targeted
metabolic activity. Stable-isotope measure-
ments are increasingly used to study cell
metabolism in vivo (Fernandez-Garcia, Altea-
Manzano, Pranzini, & Fendt, 2020). These are
beneficial when the metabolic gene/protein
of interest has a well-established primary
substrate and can be efficiently delivered to
the targeted tissue.
Critical Parameters
Although enzyme availability helps de-
termine cell-type-exclusive metabolic ability,
it cannot be used to quantify the levels
of metabolic activity. For example, a low-
expressing enzyme may display high enzyme
activity, which cannot be detected by gene or
protein expression levels. Additional inves-
tigation combining gene deletion, inhibitor
treatments, and metabolic profiling will be
necessary to complete the characterization for
the identified cell-type-specific metabolic sig-
natures. Another critical point is that, although
less susceptible than the metabolome, RNA
and protein profiling are not always resistant
to the tissue dissociation processes. Recent
studies have reported significant artifacts,
including the unexpected stress-induced gene
expression and the selection bias favoring
stress-resistant cell types (Butler, Hoffman,
Smibert, Papalexi, & Satija, 2018; Denisenko
et al., 2020). Finally, the instruments and
settings for mass spectrometry analyses in-
dicated in Basic Protocols 3 and 4 are based
on the current setup in our laboratories, and
they are meant to be of an illustrative nature.
Instruments from other vendors or alternative
acquisition methods might be employed for
the quantitative mass spectrometry analyses.
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